← Back to Search

All Patients: for Coronavirus (CAPTURE-2 Trial)

N/A
Waitlist Available
Led By Vicki Kalen
Research Sponsored by LumiraDx UK Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group

Summary

This trial evaluates how well the LumiraDx SARS-CoV-2 Ab Test works compared to the reference method.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Performance Evaluation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All Patients:Experimental Treatment2 Interventions
Capillary and Venous Blood Collections

Find a Location

Who is running the clinical trial?

LumiraDx UK LimitedLead Sponsor
15 Previous Clinical Trials
34,337 Total Patients Enrolled
Vicki KalenPrincipal InvestigatorEclipse Clinical Research
William SimonPrincipal InvestigatorProfessional Research Network of Kansas
2 Previous Clinical Trials
2,200 Total Patients Enrolled

Media Library

Capillary Collection & Testing Clinical Trial Eligibility Overview. Trial Name: NCT04597047 — N/A
Coronavirus Research Study Groups: All Patients:
Coronavirus Clinical Trial 2023: Capillary Collection & Testing Highlights & Side Effects. Trial Name: NCT04597047 — N/A
Capillary Collection & Testing 2023 Treatment Timeline for Medical Study. Trial Name: NCT04597047 — N/A
~29 spots leftby Nov 2025